Researchers identify new class of antifungal agents
2015-06-23
(Press-News.org) Washington, D.C. - June 23, 2015 - Researchers have identified a new class of antifungals to treat the more than 300 million people worldwide who develop serious fungal infections. The research is described in the current issue of mBio, the online open-access journal of the American Society for Microbiology.
"Fungal infections are a significant cause of morbidity and mortality worldwide and current antifungal drugs have drawbacks. These new drugs may pave the way for the development of a new class of antifungals," said principal investigator Maurizio Del Poeta, MD, a professor in the Department of Molecular Genetics and Microbiology at Stony Brook University, Stony Brook, New York.
Fungal infections are most commonly found in individuals with medical conditions that compromise the immune system, such as AIDS, or individuals who are being treated with immunosuppressives, such as those battling cancer. The three classes of antifungal drugs currently available--azoles, polyenes, and echinocandins--are far from optimal.
"Even with treatment, the mortality rate of invasive fungal infections is over 50%," said Dr. Del Poeta. "The drugs don't work that well. They are toxic, so they affect other organs, and they are static, meaning they may be able to stop a fungus from replicating but they are not able to kill the fungus." Current antifungals also have a narrow spectrum of activity, and some interact with other drugs such as chemotherapy agents and immunosuppressants."
Previous research has shown that when fungal cells lack a lipid called glucosylceramide (GlcCer), they are unable to replicate. Seeking to exploit this weakness and develop a new class of antifungals, an international group of researchers screened a synthetic drug library for compounds that target the synthesis of fungal but not mammalian GlcCer. "The enzymes that are important for the synthesis of fungal glucosylceramide are different than the ones important for the synthesis of mammalian glucosylceramide," said Dr. Del Poeta. "We thought that because the pathway is totally different, we could specifically target the fungal glucosylceramide without affecting mammalian glucosylceramide, and that is exactly what we did."
They identified two compounds, BHBM and its derivative DO, that decreased levels of fungal but not mammalian glucosylceramide. In test tube and animal studies, these compounds were highly effective against several pathogenic fungi and were well tolerated in animals. The drugs were effective when used alone or in combination with other classes of antifungals. The researchers plan to spend the next five years fine-tuning their research and identifying even more effective compounds that inhibit fungal glucosylceramide.
Serious fungal infections cause 1.3 million deaths annually worldwide. The most common and life-threatening fungal infections are cryptococcosis, candidiasis, aspergillosis, and pneumocystosis.
INFORMATION:
The research was conducted by a multidisciplinary group of researchers at Stony Brook University, Medical University of South Carolina, University of Cincinnati, University of Texas-San Antonio, University of British Columbia, Worcester Polytechnic Institute, Baylor College of Medicine, and Universidade Federal do Rio de Janeiro.
mBio® is an open access online journal published by the American Society for Microbiology to make microbiology research broadly accessible. The focus of the journal is on rapid publication of cutting-edge research spanning the entire spectrum of microbiology and related fields. It can be found online at http://mbio.asm.org. The paper can be found online at http://mbio.asm.org/content/6/3/e00647-15.
The American Society for Microbiology is the largest single life science society, composed of over 39,000 scientists and health professionals. ASM's mission is to advance the microbiological sciences as a vehicle for understanding life processes and to apply and communicate this knowledge for the improvement of health and environmental and economic well-being worldwide.
ELSE PRESS RELEASES FROM THIS DATE:
2015-06-23
Every time you've seen a plane take off or land at a hub airport, you've seen the world growing more connected, according to a new model developed by researchers at MIT.
In a study published in the journal Transportation Research Part E, the MIT team outlines a model that determines the degree to which regions around the world are connected via air transportation.
The researchers, at MIT's Laboratory for Aviation and the Environment (LAE), analyzed flight schedules between 1990 and 2012 from more than 1,100 airlines connecting over 4,600 airports around the world. ...
2015-06-23
The early diagnosis of certain types of cancer, as well as nervous system diseases such as multiple sclerosis and neuromyelitis optica, may soon be facilitated by the use of a nanometric sensor capable of identifying biomarkers of these pathological conditions.
The nanobiosensor was developed at the Federal University of São Carlos (UFSCar), Sorocaba, in partnership with the São Paulo Federal Institute of Education, Science & Technology (IFSP), Itapetininga, São Paulo State, Brazil. It was originally designed to detect herbicides, heavy metals and other ...
2015-06-23
Irvine, Calif., June 23 -- By identifying in spinal fluid how the characteristic mutant proteins of Huntington's disease spread from cell to cell, UC Irvine scientists and colleagues have created a new method to quickly and accurately track the presence and proliferation of these neuron-damaging compounds -- a discovery that may accelerate the development of new drugs to treat this incurable disease.
The researchers added that the cell-to-cell "seeding" property of these mutant proteins seems to be a critical part of the disease's progression. Their findings also advance ...
2015-06-23
A rigorous analysis of more than 20,000 medical records concludes that erectile dysfunction drugs, such as Viagra, are not a cause of melanoma, an often deadly form of skin cancer, despite the higher risk for the disease among users of these drugs. A detailed report on the research findings is to be published in the Journal of the American Medical Association online June 23.
The analysis, led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, of medical records for some 20,235 mostly white men suggests instead that the likely ...
2015-06-23
DURHAM, N.C. - Heart attack patients age 65 and older who have reduced heart function might still benefit from implanted defibrillators, according to a Duke Medicine study published in the Journal of the American Medical Association. But fewer than 1 in 10 eligible patients actually get a defibrillator within a year of their heart attacks, the study found.
Advanced age, transitions in care between the hospital and an outpatient clinic, and a mandatory waiting period to get a defibrillator after a heart attack were the most likely factors for low rates of use, according ...
2015-06-23
Among Medicare patients who experienced a heart attack from 2007 to 2010, fewer than 1 in 10 eligible patients with low ejection fraction (a measure of how well the left ventricle of the heart pumps blood with each beat) received an implantable cardioverter-defibrillator (ICD) within 1 year after the heart attack, even though ICD implantation was associated with a lower risk of death at 2 years after implantation, according to a study in the June 23/30 issue of JAMA.
More than 350,000 people experience sudden cardiac death in the United States annually. Clinical trials ...
2015-06-23
Among men in Sweden, use of erectile dysfunctions drugs with phosphodiesterase type 5 inhibitors was associated with a modest but significant increased risk of malignant melanoma, although the pattern of association raises questions about whether this association is causal, according to a study in the June 23/30 issue of JAMA.
Phosphodiesterase type 5 (PDE5; an enzyme), the target of oral erectile dysfunction (ED) drugs, is part of a pathway that has been implicated in the development of malignant melanoma. This has raised questions whether PDE5 inhibitors used to treat ...
2015-06-23
Among extremely preterm infants, early screening for the vascular disorder patent ductus arteriosus before day 3 of life was associated with a lower risk of in-hospital death and pulmonary hemorrhage, but not with differences in other severe complications, according to a study in the June 23/30 issue of JAMA.
The ductus arteriosus is a blood vessel in a fetus that bypasses pulmonary circulation by connecting the pulmonary artery directly to the ascending aorta. It usually closes within 72 hours of birth in most normal-term infants. However, failure to close is common ...
2015-06-23
In an analysis of the findings of nearly 80 randomized trials that included about 6,500 participants, there was moderate-quality evidence to support the use of cannabinoids (chemical compounds that are the active principles in cannabis or marijuana) for the treatment of chronic pain and lower-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, sleep disorders, and Tourette syndrome, according to a study in the June 23/30 issue of JAMA.
Medical cannabis refers to the use of cannabis or cannabinoids ...
2015-06-23
An analysis of edible medical marijuana products from 3 major metropolitan areas found that many had lower amounts of key substances than labeled, which may not produce the desired medical benefit, while others contained significantly more of a certain substance than labeled, placing patients at risk of experiencing adverse effects, according to a study in the June 23/30 issue of JAMA.
As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16 percent to 26 percent of patients ...
LAST 30 PRESS RELEASES:
[Press-News.org] Researchers identify new class of antifungal agents
